Drug intelligence / Profile preview

trimipramine

Development stage
Approved
Lead developer
Sanofi
Modality
Small Molecules
Administration
Oral, Intramuscular
01

Overview

Trimipramine is a tricyclic antidepressant (TCA) primarily used to treat depression. It is structurally similar to imipramine but has more pronounced antihistaminic and sedative properties. Unlike typical TCAs, its mechanism of action is not fully understood; it appears to decrease the reuptake of norepinephrine and serotonin in the brain, thereby increasing their levels and helping restore mental balance[1][3][4]. However, some studies suggest that trimipramine has only weak effects on noradrenergic systems compared to other TCAs, and its clinical efficacy may involve atypical actions on central nervous system pathways[6]. Trimipramine also exhibits anxiolytic and sedative effects, making it useful for patients with comorbid anxiety or sleep disturbances[8].

Brand names
Surmontil
02

Targets

mAChR (Muscarinic acetylcholine receptors)DAT (Dopamine plasma membrane transport protein)HRH1 (Histamine H1 Receptor)ADRA1A (α1A)SERT (Sodium-dependent serotonin transporter)NET (Norepinephrine Transporter)ADRA2A (α2A)5-HT (Serotonin receptors)

Beyond the preview

Go deeper on trimipramine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on trimipramine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call